Publications by authors named "A Kriplani"

Background Polycystic ovary syndrome (PCOS) poses a significant health concern among reproductive-aged women and is characterized by ovarian dysfunction, hyperandrogenism, and insulin resistance. This study aims to assess the efficacy and safety of metformin and myo-inositol combination therapy compared to metformin monotherapy in patients with PCOS. Materials and methods This was a phase III, double-blind, randomized controlled clinical trial.

View Article and Find Full Text PDF

Background: Older head and neck cancer (HNC) survivors have concerning rates of potentially unsafe opioid prescribing. Identifying the specialties of opioid prescribers for HNC survivors is critical for targeting the settings for opioid safety interventions. This study hypothesized that oncology and surgery providers are primarily responsible for opioid prescriptions in the year after treatment but that primary care providers (PCPs) are increasingly involved in prescribing over time.

View Article and Find Full Text PDF
Article Synopsis
  • Cetuximab is a standard treatment for head and neck squamous cell carcinoma (HNSCC), but resistance can occur due to activation of certain receptor tyrosine kinases; cabozantinib is an inhibitor that shows promise in overcoming this resistance.
  • A phase I trial tested the safety and efficacy of combining cetuximab with cabozantinib in patients with recurrent/metastatic HNSCC, establishing the maximally tolerated dose of cabozantinib at 60 mg without dose-limiting toxicities.
  • The trial reported a 20% overall response rate, a 75% disease control rate, and manageable toxicity, suggesting that this treatment combination is worth further study, especially in patients who have
View Article and Find Full Text PDF

We aimed to understand experiences with opioids and cannabis for post-treatment cancer survivors. We conducted seven focus groups among head and neck and lung cancer survivors, using standard qualitative methodology to explore themes around 1) post-treatment pain and 2) utilization, perceived benefits and perceived harms of cannabis and opioids. Survivors (N = 25) experienced addiction fears, stigma and access challenges for both products.

View Article and Find Full Text PDF